Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bauernfeind, A. Articles by Roller, C. Search for Related Content PubMed PubMed Citation Articles by Bauernfeind, A. Articles by Roller, C.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, September 1998, p. 2748-2751, Vol. 36, No. 9
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Discrimination of Burkholderia gladioli from Other Burkholderia Species Detectable in Cystic Fibrosis Patients by PCR

Adolf Bauernfeind,^* Ines Schneider, Renate Jungwirth, and Carsten Roller

Department of Experimental Medical Microbiology and Cystic Fibrosis, Max von Pettenkofer Institute, D-80336 Munich, Germany

Received 31 January 1998/Returned for modification 2 April 1998/Accepted 11 June 1998

	ABSTRACT

Top Abstract Text References

A procedure for molecular identification of Burkholderia gladioli is described. Specific 16S and 23S rRNA gene signature sequences were defined as primers for PCR. The method allows rapid and specific discrimination of B. gladioli from related species (B. cepacia, B. multivorans, B. vietnamiensis, B. mallei, B. pseudomallei, Ralstonia pickettii, and R. eutropha) and should contribute to the clarification of its role as a human pathogen, e.g., in cystic fibrosis.

	TEXT

Top Abstract Text References

Burkholderia gladioli (26), previously Pseudomonas gladioli (20), was described by McCulloch in 1921 (17, 18) as P. marginata, a phytopathogen causing a leaf and corm disease of gladioli and other flowers (e.g., iris species). It has been associated with human pulmonary infections, namely, of chronic granulomatous disease (10, 21) and cystic fibrosis (3, 6, 12, 19, 22, 25). The assessment of the clinical significance of B. gladioli in cystic fibrosis is controversial. Clarification has been impaired by uncertain differentiation of B. gladioli and B. cepacia by phenotypic procedures (3). Therefore, we developed a molecular procedure to identify B. gladioli. 16S and 23S rRNA gene (rDNA) sequences were screened for signatures specific for B. gladioli. They were used to establish a rapid and specific PCR procedure which discriminates B. gladioli from related species.

Organisms. For characterizations of the strains used in this study, see Table 3.

Nucleic acid preparation. Genomic DNA was prepared and purified by using the QiaAmp purification kit (Qiagen, Hilden, Federal Republic of Germany [FRG]).

PCR. Custom oligonucleotide primers (see Table 2) were purchased from MWG Biotech, Ebersberg, FRG. Amplification reactions were performed in a 50-µl final volume with 1 U of Taq polymerase (Boehringer, Mannheim, FRG), 5 µl of the reaction buffer supplied by the manufacturer (diluted 1:10), each deoxynucleoside triphosphate at 10 µM, and each oligonucleotide primer 50 pM. Approximately 50 to 100 ng of DNA was used as the template. To avoid reading mistakes, the Expand High Fidelity PCR System (Boehringer) with a proofreading polymerase was used. The PCR was performed with GeneAmp PCR System 9600 (Applied Biosystems, Weiterstadt, FRG) under the following conditions: denaturation for 5 min at 95°C and then 25 amplification cycles of 30 s at 95°C, 30 s at the annealing temperature specific for the respective primers, and 45 s at 72°C. The samples were then incubated at 72°C for another 7 min and cooled to 4°C. Pyrogen-free water that had been shown to be free of contaminating DNA was used throughout the study. To inactivate contaminating DNA, the PCR mixture was exposed to UV light for 15 min prior to enzyme and template addition. To ascertain reproducibility, all species identifications by PCR were performed in duplicate, each time starting with new cultures.

The amplification products were checked by agarose gel electrophoresis and purified of salt and excess primers by using a PCR purification kit from Qiagen.

View larger version (20K): [in this window] [in a new window]   FIG. 1.   Alignment of the 16S rDNA within the variable helix 18 region and the variable helix 37 and 38 region. The underlined bases are the target signatures for B. gladioli- and B. cepacia-specific PCR primers. Nucleotide numbering is in accordance with Escherichia coli rDNA numbering (4). Bg.DSM, B. gladioli DSM 4285; Bg.X67038, B. gladioli ATCC 10248T (13); Bg.S55001, B. gladioli EY3258 (27); Bg.FC329, Bg.H129, Bg.H176, and Bg.CEP025, B. gladioli cystic fibrosis isolates (this study); Bc.type, B. cepacia LMG 1222T (this study); Bc.M22518, B. cepacia LMG 1222T (8); Bc.X87275, B. cepacia DSM 50181 (15); Bc.L28675, B. cepacia G4 (16); Bc.IN 122, B. cepacia cystic fibrosis isolate (this study). Wobble base: Y = C or T.

Agarose gel electrophoresis. Agarose gel electrophoresis was performed as described previously (2).

Sequence determination. The amplified rDNA was sequenced as described previously (14). The two DNA strands were sequenced from different PCR products. A 373A DNA Sequencer (Applied Biosystems) was used, and the protocol of the manufacturer for dye terminator reactions was followed.

Analysis of the sequence data. The nucleotide sequences were aligned with reference rDNA sequences provided in the noncommercial software program package ARB (beta-version 2.4). Secondary-structure analysis was done as described by Ludwig et al. (15).

Nucleotide sequence accession number. The 23S rDNA sequence of B. gladioli DSM 4285 has been deposited in the EMBL database under accession no. Y17182.

16S and 23S rDNA sequences. 16S rDNA sequences of three B. cepacia strains (9, 15, 16) and two B. gladioli strains (13, 27) had already been published. The 23S rDNA of B. cepacia DSM 50181 (X16368) was also available (11). No 23S rDNA sequence of B. gladioli had yet been described. We therefore determined the 23S rDNA gene sequence of B. gladioli DSM 4285 (2,882 bp). Partial 16S and 23S rDNA sequences of additional strains (four of B. gladioli and two of B. cepacia) from various sources were also determined (Fig. 1 and 2).

View larger version (14K): [in this window] [in a new window]   FIG. 2.   Alignment of the 23S rDNA within the helix 9 and 10 regions and within the variable helix 45 region. The underlined bases are the target signature for B. gladioli- and B. cepacia-specific PCR primers. Nucleotide numbering is in accordance with E. coli rDNA numbering (5). Bg.DSM, B. gladioli DSM 4285; Bg.FC329, Bg.H129, Bg.H176, and Bg.CEP025, B. gladioli cystic fibrosis isolates (this study); Bc.type, B. cepacia LMG 1222T; Bc.X16368, B. cepacia DSM 50181 (11); Bc.IN 122 and Bc.C5424, B. cepacia cystic fibrosis isolates (this study). The asterisks indicate that there was no nucleotide at this position, in contrast to E. coli.

Analysis of 16S and 23S rDNAs for signature sequences. The prerequisite for discrimination of species by their S rDNAs are interspecies sequence deviations and their consistency among different strains of one species. There should be no or only low intraspecies sequence variability within the signature sequence section. Both conditions were checked by multiple sequence alignment of the hypervariable regions within the 16S and 23S rDNAs. Interspecies sequence deviations were identified in the helix 18a/18b region of the 16S rDNA. Within a region of the appropriate length for a primer (e.g., 18-mer), no intraspecies variability was detected among the seven B. gladioli strains and only one variable position (472) was found in B. cepacia. In the helix 37a/37b region, B. cepacia presents both consistent interspecies deviations (at four positions) and only minor intraspecies sequence variations. Therefore, this region might be exploited for a signature sequence specific for B. cepacia. Within the 23S rDNA hypervariable regions, only the helix 45a/b section carries useful interspecies differences (for B. gladioli at five positions and for B. cepacia at six positions) without major intraspecies variability (at two positions each for B. gladioli and B. cepacia). Altogether, five candidates for species-specific sequences were identified. They are characterized in Table 1.

View this table: [in this window] [in a new window]   TABLE 1.   Primers selected for PCR

Selection of primers for PCR. The aim was to establish a procedure which allows discrimination of strains of both species by a single PCR. Thus, the selection of primers was guided towards PCR products of different lengths for either species. Therefore, a constant sense primer (annealing to a DNA target common to both species) was paired with a primer specific for either B. gladioli or B. cepacia or B. cepacia plus B. multivorans that, however, anneals at a distance different from that of the sense primer (Table 2). The PCR products obtained with different sets of primers are shown in Fig. 3, which demonstrates the efficacy and specificity of the proposed primers both alone and in combination.

View this table: [in this window] [in a new window]   TABLE 2.   Primer combinations and specificity and PCR product size

View larger version (50K): [in this window] [in a new window]   FIG. 3.   Primer combinations and PCR products of two different sizes. Lanes: SM, DNA molecular size markers; 1, CMG-16-1 plus G-16-2 and CMG-23-1 plus CM-23-2 (PCR products obtained with B. gladioli [468 bp] and B. cepacia [388 bp]); 2, CMG-16-1 plus G-16-2 (B. gladioli product [468 bp]); 3, CMG-23-1 plus G-23-2 (B. gladioli product [388 bp]); 4, CMG-16-1 plus G-16-2 (no PCR product obtained with B. cepacia); 5, CMG-23-1 plus G-23-2 (no PCR product obtained with B. cepacia); 6, CMG-16-1 plus CM-16-2 (B. cepacia product [468 bp]); 7, CMG-23-1 plus CM-2-2 (B. cepacia product [388 bp]); 8, CMG-16-1 plus CM-16-2 (no PCR product obtained with B. gladioli); 9, CMG-23-1 plus CM-23-2 (no PCR product obtained with B. gladioli); 10, CMG-16-1 plus CM-16-2 and CMG-23-1 plus G-23-2 (PCR products obtained with B. cepacia [468 bp] and B. gladioli [388 bp]). The first letters(s) of the species from which PCR products were obtained is underlined.

Evaluation of primer specificity. The abilities of the primers to initiate the synthesis of species-specific PCR products were evaluated with strains of various Burkholderia and Ralstonia species from type culture collections (Table 3). Either no PCR products or amplification products of the expected sizes were found (Table 3). Furthermore, three strains each of P. aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter baumannii were investigated for cross-reactivity with the selected primers. No PCR product was detected with these strains (data not shown).

View this table: [in this window] [in a new window]   TABLE 3.   Strains and PCR results

Comparison of species identifications by PCR and by biochemical tests of clinical isolates. A number of Burkholderia strains isolated from cystic fibrosis patients at various centers in Europe and Canada were identified to the species level by biochemical reactions as proposed by Vandamme et al. (24). Their phenotypic identification was confirmed by the PCR procedure (Table 3). However, three strains sent to our laboratory as B. cepacia were found to be B. gladioli by PCR.

B. gladioli has been associated with lung infections in humans with an impaired host defense, e.g., in chronic granulomatous disease (10, 21), where a genetic defect causes ineffective killing mainly of pathogens producing catalase (such as B. gladioli). B. gladioli was first isolated from sputa of patients suffering from cystic fibrosis by Mortensen et al. (19) and Christenson et al. (6) and was then regarded as a commensal. In contrast, Khan et al. (12) described the growth of B. gladioli (without P. aeruginosa) in the sputum of a cystic fibrosis patient before lung transplantation, in the explant, and on postoperative day 40 in abscess drainage fluid, pleural fluid, and two sets of blood cultures. The patient died 6 months after lung transplantation. Those authors considered B. gladioli to be a pathogen of cystic fibrosis patients who undergo lung transplantation. Wilsher et al. (26) reported on six patients with cystic fibrosis in whose sputa the same ribotype of B. gladioli grew. All six patients died of respiratory failure between 1 and 20 months after acquisition of B. gladioli, one from fulminant B. gladioli septicemia. This is the first report of B. gladioli septicemia in a patient with cystic fibrosis. Simpson et al. (22) and Baxter et al. (3) described strains isolated from cystic fibrosis patients which could not unambiguously be identified either as B. cepacia or B. gladioli and therefore were supposed possibly to represent intermediates between the two species.

These reports demonstrate the controversy about the role of B. gladioli in the clinical course of cystic fibrosis. This is partly due to a deficit of procedures for unequivocal identification of B. gladioli in routine diagnostic laboratories (9, 25). Baxter et al. (3) reported that none of nine tests selected from the literature for their potential to differentiate between B. gladioli and B. cepacia produced clear-cut results. Furthermore, 7 of the 32 strains investigated possessed about equal characteristics of both species and were therefore regarded as hybrids. The API 20NE kit falsely identifies B. gladioli as B. cepacia. More reliable identification is achievable by analysis of the fatty acid methyl ester profile (3, 7, 22, 23). In addition, DNA-DNA hybridization was used to differentiate B. gladioli and B. cepacia (1, 6, 25). These procedures are, however, usually not established in laboratories for routine diagnostic use.

Our approach for discrimination of B. gladioli and B. cepacia is based upon the genetic diversity of S rDNAs between the two species. The primers designed for distinction between B. gladioli and B. cepacia were selected to generate amplicons of clearly different sizes for the two species and for not cross-reacting with other Burkholderia (B. pseudomallei and B. mallei) and Ralstonia (Ralstonia pickettii and Ralstonia eutropha) species (Table 3). Therefore, a PCR-based procedure for specific identification of B. gladioli was established. Its main utility in clinical laboratories is more rapid identification of strains grown on selective media (5 h versus up to 5 days) and, furthermore, clarification of uncertain species identification by biochemical reactions. The PCR technique has been established in the majority of clinical laboratories, so there is adequate equipment and technical know-how to allow the use of this procedure in a reliable way.

The procedure is inadequate for discrimination of B. cepacia genomovars I, III, and IV. It should, however, contribute to the clarification of the role of B. gladioli and other Burkholderia species in cystic fibrosis.

	ACKNOWLEDGMENTS

We thank H. Bärmeier, Erlangen, Germany; J. Dankert, Amsterdam, The Netherlands; J. Govan, Edinburgh, Scotland; N. Høiby, Copenhagen, Denmark; F. Ratjen, Essen, Germany; D. P. Speert, E. Mahenthiralingam, and D. Henry, Vancouver, British Columbia, Canada; and B. Tümmler, Hannover, Germany, for providing Burkholderia sp. isolates from cystic fibrosis patients. We particularly thank P. Vandamme, Gent, Belgium, for stimulating discussions and verification of the species identifications obtained by the PCR procedure described.

	FOOTNOTES

^* Corresponding author. Mailing address: Department of Experimental Medical Microbiology and Cystic Fibrosis, Max-von-Pettenkofer-Institute, Pettenkoferstraße 9a, D-80336 München, Germany. Phone: 0049-89-5160-5268. Fax: 0049-89-5160-5266. E-mail: Adolf.Bauernfeind{at}mvp-bak.med.uni-muenchen.de.

	REFERENCES

Top Abstract Text References

1.	Ballard, R. W., N. J. Palleroni, M. Doudoroff, and R.Y. Stanier. 1970. Taxonomy of the aerobic pseudomonads: Pseudomonas cepacia, P. marginata, P. alliicola, and P. caryophylli. J. Gen. Microbiol. 60:199-214[Abstract/Free Full Text].
2.	Bauernfeind, A., C. Roller, D. Meyer, R. Jungwirth, and I. Schneider. 1998. Molecular procedure for rapid detection of Burkholderia mallei and Burkholderia pseudomallei. J. Clin. Microbiol. 36:2737-2741[Abstract/Free Full Text].
3.	Baxter, I. A., P. A. Lambert, and I. N. Simpson. 1997. Isolation from clinical sources of Burkholderia cepacia possessing characteristics of Burkholderia gladioli. J. Antimicrob. Chemother. 39:169-175[Abstract/Free Full Text].
4.	Brosius, J., M. L. Palmer, P. J. Kennedy, and H. F. Noller. 1978. Complete nucleotide sequence of a 16S ribosomal RNA gene from Escherichia coli. Proc. Natl. Acad. Sci. USA 75:4801-4805[Abstract/Free Full Text].
5.	Brosius, J., T. Dull, and H. F. Noller. 1981. Gene organisation and primary structure of a ribosomal RNA operon of Escherichia coli. J. Mol. Biol. 148:107-127[Medline].
6.	Christenson, J. C., D. F. Welch, G. Mukwaya, M. J. Muszynski, R. E. Weaver, and D. J. Brenner. 1989. Recovery of Pseudomonas gladioli from respiratory tract specimens of patients with cystic fibrosis. J. Clin. Microbiol. 27:270-273[Abstract/Free Full Text].
7.	Dees, S. B., D. G. Hollis, R. E. Weaver, and C. W. Moss. 1983. Cellular fatty acid composition of Pseudomonas marginata and closely associated bacteria. J. Clin. Microbiol. 18:1073-1078[Abstract/Free Full Text].
8.	Dewhirst, F. E., B. J. Paster, and P. L. Bright. 1991. EMBL database accession no. M 22518.
9.	Henry, D. A., M. E. Campbell, J. J. LiPuma, and D. P. Speert. 1997. Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. J. Clin. Microbiol. 35:614-619[Abstract].
10.	Hoare, S., and A. J. Cant. 1996. Chronic granulomatous disease presenting as severe sepsis due to Burkholderia gladioli. Clin. Infect. Dis. 23:411[Medline].
11.	Höpfl, P., W. Ludwig, K.-H. Schleifer, and N. Larsen. 1989. The 23S ribosomal RNA higher-order structure of Pseudomonas cepacia and other procaryotes. Eur. J. Biochem. 185:355-364[Medline].
12.	Khan, S. U., S. M. Gordon, P. C. Stillwell, T. J. Kirby, and A. C. Arroliga. 1996. Empyema and bloodstream infection caused by Burkholderia gladioli in a patient with cystic fibrosis after lung transplantation. Pediatr. Infect. Dis. J. 15:637-639[Medline].
13.	Li, X., T. Del Dot, M. Dorsh, E. Stackebrandt, L. I. Sly, and A. C. Hayward. 1993. Phylogenetic studies on rRNA group II Pseudomonas using 16S rRNA sequences. J. Appl. Bacteriol. 74:324-329.
14.	Ludwig, W., G. Kirchhof, N. Klugbauer, M. Weizenegger, D. Betzl, M. Ehrmann, C. Hertl, S. Jilg, R. Tatzel, H. Zitzelsberger, S. Liebl, M. Hochberger, D. Lane, P. R. Wallnöfer, and K.-H. Schleifer. 1992. Complete 23S ribosomal RNA sequences of Gram-positive bacteria with a low DNA G+C content. Syst. Appl. Microbiol. 15:487-501.
15.	Ludwig, W., R. Rosselló-Mora, R. Aznar, S. Klugbauer, S. Spring, K. Reetz, C. Beimfohr, E. Brockmann, G. Kirchhof, S. Dorn, M. Bachleitner, N. Klugbauer, N. Springer, D. Lane, R. Nietupsky, M. Weizenegger, and K.-H. Schleifer. 1995. Comparative sequence analysis of 23S rRNA from Proteobacteria. Syst. Appl. Microbiol. 18:164-188.
16.	Massol-Deya, A., R. Weller, L. Rios-Hernandez, J. Z. Zhou, R. F. Hickey, and J. M. Tiedge. 1997. Succession and convergence of biofilm communities in fixed-film reactors treating aromatic hydrocarbons in groundwater. Appl. Environ. Microbiol. 63:270-276[Abstract].
17.	McCulloch, L. 1921. A bacterial disease of gladiolus. Science 54:115-116[Free Full Text].
18.	McCulloch, L. 1924. A bacterial blight of gladioli. J. Agric. Res. 27:225-230.
19.	Mortensen, J. B., D. V. Schidlow, and E. M. Stahl. 1988. Pseudomonas gladioli (marginata) isolated from a patient with cystic fibrosis. Clin. Microbiol. Newsl. 10:29-30.
20.	Palleroni, N. J. 1984. Genus I. Pseudomonas Migula 1894, 237AL, p. 141-199. In N. R. Krieg, and J. G. Holt (ed.), Bergey's manual of systematic bacteriology, vol. 1. The Williams & Wilkins, Co., Baltimore, Md.
21.	Ross, J. P., S. M. Holland, V. J. Gill, E. S. DeCarlo, and J. I. Gallin. 1995. Severe Burkholderia (Pseudomonas) gladioli infection in chronic granulomatous disease: report of two successfully treated cases. Clin. Infect. Dis. 21:1291-1293[Medline].
22.	Simpson, I. N., J. Finlay, D. J. Winstanley, N. Dewhurst, J. W. Nelson, S. L. Butler, and J. R. W. Govan. 1994. Multi-resistance isolates possessing characteristics of both Burkholderia (Pseudomonas) cepacia and Burkholderia gladioli from patients with cystic fibrosis. J. Antimicrob. Chemother. 34:353-361[Abstract/Free Full Text].
23.	Stead, D. E. 1992. Grouping of plant-pathogenic and some other Pseudomonas spp. by using cellular fatty acid profiles. Int. J. Syst. Bacteriol. 42:281-295.
24.	Vandamme, P., B. Holmes, M. Vancannyet, T. Coenye, B. Hoste, R. Coopman, H. Revets, S. Lauwers, M. Gillis, K. Kersters, and J. R. W. Govan. 1997. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int. J. Syst. Bacteriol. 47:1188-1200[Abstract/Free Full Text].
25.	Welch, D. F., M. J. Muszynski, C. H. Pai, M. J. Marcon, M. M. Hribar, P. H. Gilligan, J. M. Matsen, P. A. Ahlin, B. C. Hilman, and S. A. Chartrand. 1987. Selective and differential medium for recovery of Pseudomonas cepacia from the respiratory tracts of patients with cystic fibrosis. J. Clin. Microbiol. 25:1730-1734[Abstract/Free Full Text].
26.	Wilsher, M. L., J. Kolbe, A. J. Morris, and D. F. Welch. 1997. Nosocomial acquisition of Burkholderia gladioli in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 155:1436-1440[Abstract].
27.	Yabuuchi, E., Y. Kosako, H. Oyaizu, I. Yano, H. Hotta, Y. Hashimoto, T. Ezaki, and M. Arakawa. 1992. Proposal of Burkholderia gen. nov. and transfer of seven species of the genus Pseudomonas homology group II to the new genus, with the type species Burkholderia cepacia (Palleroni and Holmes, 1981) comb. nov. Microbiol. Immunol. 36:1251-1275[Medline].

---

Journal of Clinical Microbiology, September 1998, p. 2748-2751, Vol. 36, No. 9
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

This article has been cited by other articles:

• Segonds, C., Clavel-Batut, P., Thouverez, M., Grenet, D., Le Coustumier, A., Plesiat, P., Chabanon, G. (2009). Microbiological and Epidemiological Features of Clinical Respiratory Isolates of Burkholderia gladioli. J. Clin. Microbiol. 47: 1510-1516 [Abstract] [Full Text]  
• Lestin, F., Kraak, R., Podbielski, A. (2008). Two Cases of Keratitis and Corneal Ulcers Caused by Burkholderia gladioli. J. Clin. Microbiol. 46: 2445-2449 [Abstract] [Full Text]  
• Levy, A., Chang, B. J., Abbott, L. K., Kuo, J., Harnett, G., Inglis, T. J. J. (2003). Invasion of Spores of the Arbuscular Mycorrhizal Fungus Gigaspora decipiens by Burkholderia spp.. Appl. Environ. Microbiol. 69: 6250-6256 [Abstract] [Full Text]  
• Cunha, M. V., Leitao, J. H., Mahenthiralingam, E., Vandamme, P., Lito, L., Barreto, C., Salgado, M. J., Sa-Correia, I. (2003). Molecular Analysis of Burkholderia cepacia Complex Isolates from a Portuguese Cystic Fibrosis Center: a 7-Year Study. J. Clin. Microbiol. 41: 4113-4120 [Abstract] [Full Text]  
• Ferroni, A., Sermet-Gaudelus, I., Abachin, E., Quesne, G., Lenoir, G., Berche, P., Gaillard, J.-L. (2002). Use of 16S rRNA Gene Sequencing for Identification of Nonfermenting Gram-Negative Bacilli Recovered from Patients Attending a Single Cystic Fibrosis Center. J. Clin. Microbiol. 40: 3793-3797 [Abstract] [Full Text]  
• Brisse, S., Stefani, S., Verhoef, J., Van Belkum, A., Vandamme, P., Goessens, W. (2002). Comparative Evaluation of the BD Phoenix and VITEK 2 Automated Instruments for Identification of Isolates of the Burkholderia cepacia Complex. J. Clin. Microbiol. 40: 1743-1748 [Abstract] [Full Text]  
• Mahenthiralingam, E., Bischof, J., Byrne, S. K., Radomski, C., Davies, J. E., Av-Gay, Y., Vandamme, P. (2000). DNA-Based Diagnostic Approaches for Identification of Burkholderia cepacia Complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia Genomovars I and III. J. Clin. Microbiol. 38: 3165-3173 [Abstract] [Full Text]  
• Whitby, P. W., Carter, K. B., Hatter, K. L., LiPuma, J. J., Stull, T. L. (2000). Identification of Members of the Burkholderia cepacia Complex by Species-Specific PCR. J. Clin. Microbiol. 38: 2962-2965 [Abstract] [Full Text]  
• Brisse, S., Verduin, C. M., Milatovic, D., Fluit, A., Verhoef, J., Laevens, S., Vandamme, P., Tümmler, B., Verbrugh, H. A., van Belkum, A. (2000). Distinguishing Species of the Burkholderia cepacia Complex and Burkholderia gladioli by Automated Ribotyping. J. Clin. Microbiol. 38: 1876-1884 [Abstract] [Full Text]  
• Richau, J. A., Leitão, J. H., Correia, M., Lito, L., Salgado, M. J., Barreto, C., Cescutti, P., Sá-Correia, I. (2000). Molecular Typing and Exopolysaccharide Biosynthesis of Burkholderia cepacia Isolates from a Portuguese Cystic Fibrosis Center. J. Clin. Microbiol. 38: 1651-1655 [Abstract] [Full Text]  
• Whitby, P. W., Pope, L. C., Carter, K. B., LiPuma, J. J., Stull, T. L. (2000). Species-Specific PCR as a Tool for the Identification of Burkholderia gladioli. J. Clin. Microbiol. 38: 282-285 [Abstract] [Full Text]  
• van Pelt, C., Verduin, C. M., Goessens, W. H. F., Vos, M. C., Tümmler, B., Segonds, C., Reubsaet, F., Verbrugh, H., van Belkum, A. (1999). Identification of Burkholderia spp. in the Clinical Microbiology Laboratory: Comparison of Conventional and Molecular Methods. J. Clin. Microbiol. 37: 2158-2164 [Abstract] [Full Text]  
• HART, C A, WINSTANLEY, C (1999). Pseudomonas and all that. Arch. Dis. Child. 81: 2-4 [Full Text]  
• Bauernfeind, A., Schneider, I., Jungwirth, R., Roller, C. (1999). Discrimination of Burkholderia multivorans and Burkholderia vietnamiensis from Burkholderia cepacia Genomovars I, III, and IV by PCR. J. Clin. Microbiol. 37: 1335-1339 [Abstract] [Full Text]  
• Bauernfeind, A., Roller, C., Meyer, D., Jungwirth, R., Schneider, I. (1998). Molecular Procedure for Rapid Detection of Burkholderia mallei and Burkholderia pseudomallei. J. Clin. Microbiol. 36: 2737-2741 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bauernfeind, A. Articles by Roller, C. Search for Related Content PubMed PubMed Citation Articles by Bauernfeind, A. Articles by Roller, C.